These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 10960717

  • 1. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
    Kato N, Mizuno K, Makino M, Suzuki T, Yagihashi S.
    Diabetes Res Clin Pract; 2000 Oct; 50(2):77-85. PubMed ID: 10960717
    [Abstract] [Full Text] [Related]

  • 2. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K, Kato N, Makino M, Suzuki T, Shindo M.
    J Diabetes Complications; 1999 Oct; 13(3):141-50. PubMed ID: 10509874
    [Abstract] [Full Text] [Related]

  • 3. Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2',5'-dioxospiro-[chroman-4,4'-imidazolidine]-2-carbox amide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats.
    Kato N, Mizuno K, Matsubara A, Nakano K, Kurono M, Yagihashi S.
    J Diabetes Complications; 1994 Oct; 8(1):27-32. PubMed ID: 8167384
    [Abstract] [Full Text] [Related]

  • 4. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K, Kato N, Matsubara A, Nakano K, Kurono M.
    Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
    Gillon KR, Hawthorne JN, Tomlinson DR.
    Diabetologia; 1983 Oct; 25(4):365-71. PubMed ID: 6416913
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat.
    Stevens MJ, Lattimer SA, Kamijo M, Van Huysen C, Sima AA, Greene DA.
    Diabetologia; 1993 Jul; 36(7):608-14. PubMed ID: 8359577
    [Abstract] [Full Text] [Related]

  • 9. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Hotta N, Kakuta H, Fukasawa H, Koh N, Sakakibara F, Nakamura J, Hamada Y, Wakao T, Hara T, Mori K.
    Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
    Sobajima H, Aoki T, Sassa H, Suzuki T, Taniko K, Makino M, Mizuno K, Suzuki T.
    Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
    [Abstract] [Full Text] [Related]

  • 11. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy.
    Dyck PJ, Zimmerman BR, Vilen TH, Minnerath SR, Karnes JL, Yao JK, Poduslo JF.
    N Engl J Med; 1988 Sep 01; 319(9):542-8. PubMed ID: 3136330
    [Abstract] [Full Text] [Related]

  • 12. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats.
    Yagihashi S, Kamijo M, Ido Y, Mirrlees DJ.
    Diabetes; 1990 Jun 01; 39(6):690-6. PubMed ID: 2140802
    [Abstract] [Full Text] [Related]

  • 13. The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat.
    Cameron NE, Leonard MB, Ross IS, Whiting PH.
    Diabetologia; 1986 Mar 01; 29(3):168-74. PubMed ID: 3084324
    [Abstract] [Full Text] [Related]

  • 14. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
    Sima AA, Prashar A, Nathaniel V, Bril V, Werb MR, Greene DA.
    Diabet Med; 1993 Mar 01; 10(2):115-21. PubMed ID: 8458187
    [Abstract] [Full Text] [Related]

  • 15. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H, Tawata M, Aida K, Onaya T.
    J Clin Endocrinol Metab; 1992 Feb 01; 74(2):393-8. PubMed ID: 1370506
    [Abstract] [Full Text] [Related]

  • 16. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.
    Obrosova IG, Pacher P, Szabó C, Zsengeller Z, Hirooka H, Stevens MJ, Yorek MA.
    Diabetes; 2005 Jan 01; 54(1):234-42. PubMed ID: 15616034
    [Abstract] [Full Text] [Related]

  • 17. Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat.
    Kuzumoto Y, Kusunoki S, Kato N, Kihara M, Low PA.
    Diabetologia; 2006 Dec 01; 49(12):3085-93. PubMed ID: 17063327
    [Abstract] [Full Text] [Related]

  • 18. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
    Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N, SNK-860 Diabetic Neuropathy Study Group.
    Diabetes Care; 2001 Oct 01; 24(10):1776-82. PubMed ID: 11574441
    [Abstract] [Full Text] [Related]

  • 19. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
    Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ.
    FASEB J; 2002 Jan 01; 16(1):123-5. PubMed ID: 11709499
    [Abstract] [Full Text] [Related]

  • 20. Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy.
    Kamijo M, Basso M, Cherian PV, Hohman TC, Sima AA.
    Diabetes Res Clin Pract; 1994 Sep 01; 25(2):117-29. PubMed ID: 7821191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.